Radioiodine therapy in patients with hyperthyroid disorder: standard versus dosimetric activity application

Nuclear Medicine Communications

Volumn 24, Issue 12, 2003, Pages 1247-1253

  Reinartz, P ^a   Zimny, M ^a   Schaefer, W ^a   Mueller, B ^a   Buell, U ^a   Sabri, O ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Iodine uptake; Radioiodine; Radioiodine test; Radioiodine therapy; Thyroid disorder

Indexed keywords

DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; IODINE 131;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTHYROIDISM; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; RADIOMETRY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STANDARD; VALIDATION STUDY; ACCURACY; CORRELATION COEFFICIENT; DOSIMETRY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG UPTAKE; HEALTH CARE PLANNING; LINEAR SYSTEM; MAJOR CLINICAL STUDY; OBSERVATION; STANDARDIZATION;

FEMALE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 3042604704     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200312000-00008     Document Type: Article

References (26)

1. Husymans DA, Hermus AR, Corstens FH, Kloppenborg PW. Long-term results of two schedules of radioiodine treatment for toxic multinodular goiter. Eur J Nucl Med 1993; 20: 1056-1062.
2. Dietlein M, Knapp WH, Lauterbach KW, Schicha H. Economic evaluation studies in nuclear medicine: the need for standardization. Eur J Nucl Med 1999; 26: 663-680.
3. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9: 1181-1188.
4. Stephen RT. Options for radionuclide therapy: from fixed activity to patient specific treatment planning. Cancer Biother 2002; 17: 71-82.
5. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993; 34: 1632-1638.
6. Nüchel C, Boddenberg B, Schicha H. The value of the radioiodine uptake test for the calculation of therapeutic doses for benign thyroid disorders. Nuklearmedizin 1993; 32: 91-98.
7. 131iodine activity - results from a prospective, randomized, multicenter study. Eur J Clin Invest 1995; 25: 186-193.
8. Sabri O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999: 84: 1229-1233.
9. Matheoud R, Canzi C, Reschini E, Zito F, Voltini F, Gerundini P. Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule. Med Phys 2003; 30: 791-798.
10. Kok SW, Smit JW, de Craen AJ, Goslings BM, van Eck-Smit BL, Romijn JA. Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nucl Med Commun 2000; 21: 1071-1078.
11. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hyperthyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002; 141: 99-103.
12. Jarlov AE, Hegedues L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol 1995; 43: 325-329.
13. Rivkees SA, Sklar C, Freemark M. The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767-3776.
14. Doi SA, Loutfi I, Al-Shoumer KA. A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC Nucl Med 2001; 1 (online publication).
15. Loevinger R, Berman M. A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol 1968; 13: 205-217.
16. Harbert JC. Radioiodine therapy of hyperthyroidism. In: Harbert JC, ed. Nuclear medicine therapy. Stuttgart: Thieme, 1987: 1-36.
17. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes. Am J Roentgenol 1948; 59: 260-281.
18. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86: 3488-3493.
19. Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 2002; 147: 1-11.
20. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87: 1073-1077.
21. Wesche MF, Tiel-van Buul MM, Smits NJ, Wiersinga WM. Ultrasonography versus scintigraphic measurement of thyroid volume in patients referred for 131I therapy. Nucl Med Commun 1998; 19: 341-346.
22. Van Isselt De Klerk JM, Van Rijk PP, et al. Comparison of methods for thyroid volume estimation in patients with Graves' disease. Eur J Nucl Med Mol Imaging 2003; 30: 525-531.
23. Reinartz P, Sabri O, Zimny M, et al. Thyroid volume measurement in patients prior to radioiodine therapy: comparison between three-dimensional magnetic resonance imaging and ultrasonography. Thyroid 2002; 12: 713-717.
24. Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clin Endocrinol 1994; 40: 803-806.
25. Wallaschofski H, Müller D, Georgi P, Paschke R. Induction of THS-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res 2002; 34: 36-39.
26. Van Isselt JW, De Klerk JM, Koppeschaar HP, Van Rijk PP. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease. Nucl Med Commun 2000; 21: 609-616.